_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
BDX
Primary Facts
Medical Instruments & Supplies
Name:
-
Sector:
486.00M
Industry:
252.84
CEO:
Mr. Thomas Polen
Total Employees:
Large Cap
Our Technological Advancement Rating
Our Rating:
-0.71888233
8.282972265
Becton, Dickinson And Company (XNYS:BDX) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
BECTON, DICKINSON AND COMPANY (XNYS:BDX)
One Month Price Target:
Six Month Price Target :
$253.65
Likely Price in One Year's Time:
Ticker:
$257.72
Likely Trading Range Today Under (Normal Volatility)
$253.6
Price Upper limit ($) :
$262.61
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P69
This week:
$243.95
This month :
$232.95
Other Primary facts
Market Cap:
285.20M
Market Cap Classification:
71.89B
Number of Shares
IPO Date:
A+
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-11.8%
$213.06
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$275.31
11.37%
$230.37
$294.13
Medium risk (<10%) entry points
Buy Call
Sell Call
$265.16
Buy Put:
Sell Put:
$211.55
$240.52
$269.18
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Instruments & Supplies
Sharpe Ratio:
BDX, is amongst the top 40% lowest yielding stocks in terms of daily returns
Comparison:
1.60%
-0.951615241
Sharpe ratio is -95.16% lower than the industry
Average Returns/Yield of
Medical Instruments & Supplies
Daily returns:
1
Weekly returns:
0.01%
Monthly returns:
0.05%
Yearly returns:
2.44%
Comparison of returns:
-0.833613704
Classification:
Average annual returns/yield (last 3 years) is -83.36% below industry average
Results of T-Test of Returns:
BDX is a comparatively less risky than Nasdaq (IXIC)
Statistical test of Returns:
0.38
Volatility (measured by Standard Deviation)
Daily Volatility:
& is -96.60% lower than the market/S&P 500 average
Weekly Volatility:
1.72%
Monthly Volatility:
3.84%
Yearly Volatility:
7.68%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
33.49%
-48.05%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -48.05% below long-term volatility
Weekly VaR:
-3.52%
Monthly VaR:
-7.87%
How Much Can the price of
Medical Instruments & Supplies
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Medium (<50%)
Worst case (decline):
$217.95
This translates to price declining to:
-14%
This translates to price declining to:
-54.50%
Severe Crash Probability
-15.73%
What is Value at Risk (VaR)?
Risk Fundamentals
-4.87%
BDX is a 11.04% riskier investment compared to the market/S&P 500 & is -4.87% less risky than Nasdaq(IXIC)
BDX is a 11.04% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Instruments & Supplies
0.575
Expected beta in 1 year's time:
0.462
Expected beta in 3 year's time:
0.575
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--0.58
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is -41.88% below industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.351
-0.426
Average Industry Beta:
Beta is -42.62% lower than peers
-0.418788619
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -38.06% below industry mean WACC
-77.36%
Alpha provided | Alpha Analysis
Alpha provided:
0.813
-1.977
-2.957
Analysis of Cost of Capital of
Medical Instruments & Supplies
Equity cost of capital:
Alpha is -296% below the market average
-0.286
Unlevered (without debt) cost of capital:
Equity cost of capital is -28.59% below industry mean WACC
Before-tax cost of debt:
4.33%
After-tax cost of debt:
2.44%
Overall debt rating:
1.93%
Weighted average cost of capital (WACC):
2.44%
-38.06%
Key Per-Share Metrics & Analysis
Revenue per share:
Present value of the expected future dividends only: $56.96
Revenue growth rate per share of (3Y):
Price to sales ratio is -51.46% below the industry mean
-74.24%
EPS:
One Billion Eight Hundred Seven Million Three Hundred Twelve Thousand One Hundred Dollars
Expected Annual growth rate of EPS (3Y):
-
16.17%
Free cash flow (FCF) per share:
Price to book ratio is -58.65% below the industry mean
Growth rate in R&D investment/expenditure is 8462.97% higher than the industry
2.722902944
Debt per share
Debt repayment rate in last quarter: 0.00%
EBITDA per share
Each employee generates -43% less EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Instruments & Supplies
P/E Ratio:
Sustainable growth rate is -77.36% below industry average
P/E Ratio of Competitors/Peers:
42.83
-0.141408345
316.300845
-0.200634447
$6.52
Share value as per dividend discount (DDM) model: $75.27
P/S (Price to Sales ratio):
$70.24
-0.514578067
P/B (Price to book value ratio):
Price to sales ratio is -51.46% below the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -74.24% below industry average
-573.85%
Dividend Analysis
Net income growth rate is -573.85% lower than the industry average net income growth rate
Dividend payout rate: 14.11%
$0.87
Previous Dividend: $0.87
Previous adjusted dividend: $0.87
Previous Dividend: $3.44
Expected next dividend best case: $0.90
Expected next dividend worst case: $0.84
Average dividend payment (long-term): $0.83
Average dividend increase/decrease (growth rate) % per period: 0.99%
Expected next dividend payment date: 28/09/2022
Expected next dividend record date: 09/07/2022
-
Previous dividend payment date: 30/06/2022
Previous dividend record date: 06/09/2022
Dividend History:
-
2022-03-09--$0.87
2021-09-08--$0.83
2022-06-08--$0.87
2021-12-09--$0.87
2021-06-08--$0.83
-1.501184366
In-depth Debt & Leverage Analysis
Debt to equity ratio:
64.24%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 0.3 years
Debt to assets ratio:
29.09%
Net debt to assets ratio:
67.71%
-14.59%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -14.59% below industry average
-0.84
Looking forward:
Debt growth rate:
1.4x
-101.62%
0.00%
Analysis of Key Statistics
Correlation of price movement with the market:
13.11080831
Statistical significance of correlation:
-0.28%
Average Correlation of the industry with the market:
0.448
-11.31%
R Squared (percentage of price movement explained by movement of the market):
0.448
Correlation of price movement with Nasdaq (^IXIC):
0.201
Covariance of price movement with the market:
0.025
Kurtosis
0.025
9.007
Skewness of returns:
Returns have a significant fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
-0.460
Fundamental Analysis & Dupont Analysis of
Medical Instruments & Supplies
Gross Profit Margin Ratio:
9.18B
Operating Profit Margin Ratio:
Net profit margin is -28.36% lower than the industry
-3.41%
Net Profit Margin Ratio:
9.18B
Effective Tax Rate:
4.32%
-0.822954422
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -49.74% lower than the industry
-117.44%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -3.41% lower than the industry
-49.74%
Financial Leverage:
Interest coverage ratio is -84.28% less than industry average
Current Ratio:
Return on equity (ROE) is -117.44% lower than the industry
-0.662213614
Cash Conversion Cycle (days):
$57.36
0.235586238
Current ratio is -66.22% below industry average
Stock based compensation to net income ratio:
Equity growth rate per share is 272.29% higher than the industry
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is 23.56% above industry average
-0.244719769
EBITDA generated per employee:
Each employee generates -24% less revenue than industry average revenue per employee
-0.432633722
Profit generated per employee:
$16.61
-67%
Free cash flow (FCF) generated per employee:
Each employee generates -67% less net income/profit than industry average revenue per employee
-2.125983807
Assets/Capital per employee
Each employee generates -213% less free cash flow than industry average revenue per employee
-2.125983807
Research & Development (R&D) Analysis
22.17%
84.629686
Competitors/Peer firms of
Medical Instruments & Supplies
$338.49
EDWARDS LIFESCIENCES CORPORATION (XNYS:EW)
CIGNA CORPORATION (XNYS:CI)
HCA HEALTHCARE, INC. (XNYS:HCA)
IQVIA HOLDINGS INC (XNYS:IQV)
HUMANA INC. (XNYS:HUM)
STRYKER CORPORATION (XNYS:SYK)
ZOETIS INC. (XNYS:ZTS)
CENTENE CORPORATION (XNYS:CNC)
Current Analyst Ratings
$6.34
Strong buy�29%
Buy�13%
Hold�21%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
20.03B
10.86B
183%
1.40B
-
5.03B
1.24B
2.72B
17.35B
8.00M
425.00M
2.27B
95%
118.00M
- 562000.00K
41%
118.00M
Statement of Cash Flow
Date:
Period:
677.00M
Differed Income Tax :
557.00M
Stock Based Compensation :
- 69000.00K
Change in Working Capital :
83.00M
Accounts Receivables:
- 278000.00K
Other Working Capital:
-
Other Non-Cash Items:
-
Net Cash Provided by Operating Activities:
- 296000.00K
Investments in PP&E:
674.00M
Net Acquisitions:
-
Purchases of Investments:
- 415000.00K
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
12/31/2021
2022
Q1
1.90B
8.00M
1.91B
2.18B
3.04B
1.18B
8.31B
6.38B
24.12B
12.61B
-
-
1.95B
45.06B
-
53.36B
-
1.06B
-
-
5.67B
6.74B
16.36B
1.08B
22.47B
-
29.20B
365.00M
14.23B
- 2043000.0K
Value
9.14B
11.60B
24.16B
53.36B
-
17.42B
-
-
- 271000.00K
- 686000.00K
-
-
-
- 271000.00K
- 56000.00K
- 327000.00K
- 6000.00K
- 345000.00K
2.05B
2.39B
674.00M
- 188000.00K
Our Proprietary Portfolio Rating
Our Rating:
9911.570181
Price Forecast/Expected Price in Next 5 Years of
Medical Instruments & Supplies
2023
2024
2025
2026
2027
290.8611484
$290.86
$302.10
$313.77
$325.90